Taysha Gene Therapies, Inc. (TSHA)
NASDAQ: TSHA · Real-Time Price · USD
5.66
-0.04 (-0.70%)
Sep 2, 2026, 12:17 PM EDT - Market open
Taysha Gene Therapies Stock Forecast
Stock Price Forecast
According to 12 analysts polled by S&P Global, Taysha Gene Therapies stock has a consensus rating of "Strong Buy" and an average price target of $13.33. The average 1-year stock price forecast is 135.51% higher than the current stock price, while the lowest is $10 (+76.68%) and the highest is $19 (+235.69%).
Price Target: $13.33 (+135.51%)
Analyst Consensus: Strong Buy
Price Target
ChartAnalyst Ratings
The average analyst rating for Taysha Gene Therapies stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '26 | Apr '26 | May '26 | Jun '26 | Jul '26 | Aug '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 11 | 10 | 10 | 9 | 9 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 14 | 14 | 13 | 13 | 12 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Bank of America Securities | Bank of America Securities | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Aug 14, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $19 | Buy | Maintains | $19 | +235.69% | Aug 12, 2026 |
| Goldman Sachs | Goldman Sachs | Buy Maintains $13 | Buy | Maintains | $13 | +129.68% | Aug 12, 2026 |
| Canaccord Genuity | Canaccord Genuity | Buy Maintains $17 | Buy | Maintains | $17 | +200.35% | Aug 12, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $12 | Buy | Maintains | $12 | +112.01% | Aug 12, 2026 |
Financial Forecast
Revenue This Year
1.75M
from 9.77M
Decreased by -82.09%
Revenue Next Year
19.65M
from 1.75M
Increased by 1,023.00%
EPS This Year
-0.47
from -0.32
EPS Next Year
-0.46
from -0.47
EPS and Forward PE are based on non-GAAP adjusted numbers.